A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort Turbuhaler 320/9 μg, Compared With Seretide Diskus 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each

Trial Profile

A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort Turbuhaler 320/9 μg, Compared With Seretide Diskus 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Nov 2013

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms SPEED
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Sep 2009 Results have been presented at ERS 2009.
    • 23 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jul 2008 Status changed from recruiting to in progress, as reported on clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top